Valuation: Natera, Inc.

Market Cap 57.02B 50.95B 47.53B 43.17B 81.31B 5,516B 81.92B 571B 223B 2,805B 214B 209B 9,018B P/E 2026 *
-280x
P/E 2027 * -5,316x
Enterprise Value 55.95B 49.99B 46.64B 42.36B 79.78B 5,412B 80.38B 560B 219B 2,752B 210B 205B 8,848B EV / Sales 2026 *
19.2x
EV / Sales 2027 * 15.8x
Free-Float
97.24%
Yield 2026 *
-
Yield 2027 * -
1 day-0.52%
1 week-4.29%
Current month-4.29%
1 month+20.53%
3 months+40.63%
6 months+89.02%
Current year+72.67%
1 week 383.45
Extreme 383.45
437.41
1 month 320.65
Extreme 320.65
437.41
Current year 181
Extreme 181
437.41
1 year 167.98
Extreme 167.985
437.41
3 years 36.9
Extreme 36.9
437.41
5 years 26.1
Extreme 26.1
437.41
10 years 7.35
Extreme 7.35
437.41
Manager TitleAgeSince
Chief Executive Officer 47 01/01/2019
President 46 31/08/2023
Director of Finance/CFO 45 31/01/2017
Director TitleAgeSince
Chairman 53 30/04/2015
Director/Board Member 53 31/12/2006
Director/Board Member 47 01/01/2019
Date Insider Type Main position Quantity % Market Cap. Importance
01/10/26 Sell

Chief Executive Officer

-1,273 0.0009%
01/10/26 Sell

Executive/Senior Manager

-3,000 0.0021%
23/09/26 Other

Founder

18,064 0.0125%
Change 5-day change 1-year change 3-year change Capi.($)
-1.27%-4.29%+134.71%+808.29% 57.02B
+1.76%+2.64%+14.04%+25.82% 112B
+1.61%+2.91%+0.37%+78.98% 95.08B
-4.41%-2.18%-5.47%+55.95% 27.29B
+0.08%+1.25%+11.57%+54.91% 25.3B
-0.58%-2.58%+24.83%+82.72% 25.06B
+0.26%+0.97%-15.92%-2.43% 21.27B
+0.53%+1.67%+26.85%+321.39% 20.92B
-0.60%+15.93%+8.61%+81.18% 19.35B
-0.25%+0.64%-3.79%+35.40% 17.08B
Average -0.29%+1.70%+19.58%+154.22% 42.08B
Weighted average by Cap. +0.25%+1.45%+24.68%+167.13%

Financials

2026 *2027 *
Net sales 2.91B 2.6B 2.43B 2.2B 4.15B 281B 4.18B 29.15B 11.39B 143B 10.92B 10.69B 460B 3.51B 3.14B 2.93B 2.66B 5.01B 340B 5.04B 35.17B 13.74B 173B 13.18B 12.89B 555B
Net income -200M -179M -167M -151M -285M -19.34B -287M -2B -783M -9.84B -751M -734M -31.62B -1.89M -1.69M -1.57M -1.43M -2.69M -183M -2.71M -18.92M -7.39M -92.94M -7.09M -6.94M -299M
Net Debt -1.07B -958M -894M -812M -1.53B -104B -1.54B -10.74B -4.2B -52.75B -4.03B -3.94B -170B -1.39B -1.24B -1.16B -1.05B -1.98B -134B -1.99B -13.91B -5.43B -68.3B -5.21B -5.1B -220B
Projected Income Statement - Annual - Natera, Inc.
Logo Natera, Inc.
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
Employees
6,138
Date Price Change Volume
07/10/26 US$395.56 -1.27% 2,816,863
06/10/26 US$400.65 -5.87% 2,499,462
05/10/26 US$425.64 +3.73% 2,021,831
02/10/26 US$410.35 +0.46% 2,156,455
01/10/26 US$408.47 -1.17% 1,864,194
Trader
Investor
-
Global
-
Quality
ESG MSCI
BB
Ratings Surperformance© - Natera, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
395.56USD
Average target price
383.66USD
Spread / Average Target
-3.01%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Natera, Inc.
  1. Stock Market
  2. Stocks
  3. NTRA Stock